Trial Profile
Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Depreivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Bicalutamide; Goserelin; Leuprorelin
- Indications Adenocarcinoma; Cancer metastases; Prostate cancer
- Focus Therapeutic Use
- 09 May 2023 Status changed from active, no longer recruiting to completed.
- 02 Mar 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 02 Mar 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.